Amber, a transpersonal psychotherapist, discusses the healing potential of non-ordinary states of consciousness.
Similar Posts
MindMed Added To The Russell 3000 and The MSCI Canada Index [Where Does MNMD/MMED Go From Here?]
MindMed (NASDAQ: MNMD), (MMED: NEO) has been added to two major indexes; the Russell 3000 and the Morgan Stanley Capital International Canada Index.
In this segment we will explain what that means and how this news will influence the stock price.
Links:
MindMed (MMED / MNMD) added to the Russell 3000:
https://www.reddit.com/r/MindMedInvestorsClub/comments/nsle8l/mnmd_added_to_the_russell_3000_index/
https://www.reddit.com/r/MindMedInvestorsClub/comments/nsqcz5/big_news_mindmed_has_been_added_to_one_of_the/
MindMed added to the MSCI Canada Index:
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/neo-exchange-announces-eligibility-in-msci-indexes
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindmedNews
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward
When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.
In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.
Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/
MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/
Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #MindMed #Cybin
How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more
Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.
Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.
Timestamps:
0:00 – Intro
1:34 – What is the clinical trial system?
2:15 – Preclinical
3:00 – Phase 0
3:32 – Phase I
5:45 – Phase II
8:26 – Phase III
10:28 – Phase IV
11:08 – Who’s winning the race?
11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Numi #CMPS
Healing Maps: From Ketamine Clinics to Psychedelic Retreats | The Yelp of Psychedelic Therapies
In today’s episode, Psychedelic Spotlight sits down with the founders…